OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

PROSTATE i CANCER UK ANNUAL REPORT AND FINANCIAL STATEMENTS 2024/25

Additional information

Company number

02653887 in England and Wales

Charity number

1005541 in England and Wales SCO39332 in Scotland

Registered office

Fourth Floor The Counting House 53 Tooley Street London SE1 2QN prostatecanceruk.org

Company secretary

Rajit Gholap

Patron

HRH The Duchess of Gloucester, LG, GCVO, DStJ, CD

President

Professor Jonathan Waxman OBE

Chartered accountants and statutory auditors

HaysMac LLP 10 Queen Street Place London EC4R 1AG

Bankers

National Westminster Bank plc Park Royal Branch 1 Abbey Road London NW10 7RA

Investment advisors

Cazenove & Co 1 London Wall Place London EC2Y 5AU

Legal advisor Macfarlanes LLP 20 Cursitor Street London EC4A 1LT

2

Contents

Page

3

Introduction from our Chief Executive and Chair

Today, prostate cancer is the most common cancer in men. In fact, 1 in 8 of our dads, brothers, grandads and mates will be diagnosed with the disease.

Despite this, there’s no national screening programme inviting men for regular tests to help find it early. And that means there are still far too many men being diagnosed when it’s too late.

This is our challenge. But thanks to your support this year, we’re leading the way towards a better future for men. It’s a future where early diagnosis will be the norm, giving men better treatment options. Where a faster, fairer health system will work for every man – regardless of race or postcode. Where men will have more time to do the things they love, with family and friends alongside them.

But we can only get there with our extraordinary supporters by our side.

This was a year in which prostate cancer cut through the public consciousness like never before. Highprofile celebrities like Sir Chris Hoy came forward to share their diagnosis, talk publicly about the disease and bang the drum for risk awareness.

And we spearheaded transformative partnerships with the likes of Omaze , M&S , Paddy Power and the MOBO Awards to reach record numbers of men with our lifesaving message. All while continuing to be the biggest funder of prostate cancer research in the UK, investing in cutting-edge science and innovation to transform men’s health.

So I’d like to say a sincere thank you for standing with us this year and helping us move closer to a world where no man dies of prostate cancer.

Laura Kerby Doris Olulode Chief Executive Officer Chair

4

Trustees’ Report

Structure, governance and management

Objects

The charity’s objects, set out in its Articles of Association which is its governing document, are to support and invest in prostate cancer research and to publish useful results from that research; to raise public awareness of prostate cancer and other prostate diseases; and to provide information and support to men and their families affected by prostate cancer and other prostate diseases

This report contains the strategic report, required under Section 414C(11) of the Companies Act 2006, which summarises the charity’s activities, achievements and performance.

Structure

The Members of the Board of Trustees (‘The Trustees’) of Prostate Cancer UK (‘the charity’), who are also Directors of the charity for the purposes of the Companies Act, submit their annual report and the audited financial statements for the group for the year ended 31 March 2025.

The charity is a charitable company limited by guarantee and was incorporated on 14 October 1991. The Strategic Report provides information on the charity’s activity and set out below are details of its financial performance from April 2024 to March 2025.

The charity has a trading subsidiary, Prostate Cancer Trading Limited (06157784) and also owns the following dormant companies: The Prostate Cancer Charity Limited (08183613), Prostate Cancer Research Foundation (05926197) and Prostate Action (07149009).

Governance

Overall strategy and policy for the charity are agreed by the Board of Trustees, advised by the Chief Executive and other members of the Leadership Team who attend all meetings.

Articles of Association

The charity’s Articles of Association were last updated on 30 September 2025.

Trustees and Officers of the Board

Trustees, including the Chair and Vice Chair, are all elected for an initial term of three years. They are then eligible for election for a further final term of three years. These terms are extendable, exceptionally, at the discretion of the Board of Trustees.

It is our policy to look to recruit a diverse mix of Trustees from the widest field of applicants and with a good spread of relevant skills. During the year, one Trustee retired and no new Trustees were appointed.

We ensure new Trustees have the knowledge and skills to perform their roles. A number of the Trustees have been personally affected by prostate cancer. New Trustees undertake an induction programme, meeting with staff from across the charity and are provided with relevant background briefing information.

The Board of Trustees uses the Charity Governance Code as a reference point for a rolling review of governance, to ensure standards always remain high. Governance updates are provided at each meeting.

An important tool informing this governance focus is the regular Board Effectiveness Review. A comprehensive Board Effectiveness Review took place in Autumn 2024. The charity has recruited new Trustees aligned to the skills and experience needed in service of our vision.

The charity has Trustee indemnity insurance.

Trustees met on 17 occasions during the year, either as a full Board or in the committees.

5

Trustees and Directors

The Trustees and Directors who served the charity during the period were: (Trustees are members of the committees as indicated by the numbers in brackets)

Independent committee members serving during the period:

Appointed after the period:

Committees of the Board

1 - Finance, Risk and Audit Committee

2 – People, Nominations and Remuneration Committee

6

3

Health Services, Equity & Improvements Committee

4 - Board Research Committee

5 Research Advisory Committee

This Committee consists of experts with the clinical and research expertise to impartially recommend to the Board of Trustees the research projects the charity should support through our Research Innovation Awards.

Fellowships Panel

This Panel consists of experts with the clinical and research expertise to impartially recommend to the Board of Trustees which Early Career Researchers and their projects the charity should support through our Career Acceleration Fellowships.

Scientific Advisory Board

This group consists of experts with the clinical and research expertise to impartially recommend to the Board of Trustees the larger-scale research investments the charity should support through our Transformational Impact Awards. The Scientific Advisory Board also provides expert scientific insight to inform the forward direction and delivery of the charity’s research strategy.

Patient & Public Involvement

All of our funding schemes and scientific committees are supported by our Patient and Public Involvement (PPI) representatives. This group consists of people who have been affected by prostate cancer and they collectively assess the proposals we receive and contribute to our funding committees by providing the patient perspective and considering the involvement of patients in the proposed research.

Leadership Team

As at 31 March 2025, the Leadership Team, being the charity’s key management personnel, was:

7

Resigned in period:

8

Financial review

Overall performance

Our financial performance was strong in FY25, delivered from continued growth in income after a successful FY2023-24. Prostate Cancer is now the most commonly diagnosed cancer in England, a startling statistic that drove growth in philanthropic donations. To support our intention to deliver impact for men, 79p in every £1 raised was spend on charitable activities, including research, support services and awareness raising over the past 3 years.

Income (£45.5m)

----- Start of picture text -----
Donations
50.0
40.0
11.1 5.9
5.3
30.0
20.0
31.4 29.8
10.0
-
FY25 FY24
| Mass fundraising and legacies | Partnerships and philanthropy | Government grants
Donations (£m)
----- End of picture text -----

Our income increased by £1.7m (4%) to £45.5m (2024: £43.8m). We are delighted that growth was driven by contributions from a wider range of supporters who champion our cause. Our mass fundraising, including the efforts of hundreds of thousands of regular givers, one-off cash donors, events and community participants and legacies grew by £1.6m (5%).

Our donations from Events and Community remains consistent with last year (£12.8m vs £12.9m), reflecting the effort of thousands that run, cycle and play golf alongside community activity across the country to raise money for us.

9

Individual Givers, donating regularly or one-off cash gifts, and donations from legacies grew by 11%. We appreciate the dependable income from our regular givers, as this affords us the confidence to spend into our mission. We benefitted from a large number of donors, leaving higher values to us in their wills. Although the timing of these gifts remains unpredictable due to the necessary court clearance process, they play a crucial role in our long-term initiatives.

Our income from philanthropic and corporate partnerships more than doubled this year to £11.1m (2024: £5.3m). We are grateful for the support we have received from a number of donors such as Omaze, PaddyPower, John Bloor, John Black Charitable Foundation, The Mike Gooley Trailfinders Charity and The Freddie Green and Family Charitable Foundation.

No government funding was received this year (FY24/25: £5.9m), in contrast to last year when funds were restricted for specific research grants.

We were able to benefit from high interest rates to raise £2.4m (2024: £2.2m) from interest income this year. As interest rates are expected to fall in the future, we have a strategy to grow fundraising income and to diversify our investment portfolio to secure the long term growth of our cash balances.

Expenditure (£42.0m)

Our expenditure for FY25 has increased to support our ongoing organisational activities. We remain a leading UK funder of prostate cancer research, providing £11.6 million in core funding this year. The TRANSFORM investment for stage 1 of the trial was accounted as a single commitment of £13.6 million in FY24.

----- Start of picture text -----
Year on year Expenditure change
60.0
50.0
13.6
40.0
30.0
31.1
27.5
20.0
10.0
11.0 10.3
-
FY25 FY24
Cost of Generating Funds Charitable activities TRANSFORM
Expenditure (£m)
----- End of picture text -----

10

1. Research

Our continued income growth has allowed us to maintain the levels of research we fund. We awarded £11.6m (FY24 £11.5m) on our 3 core funding rounds

Our core funding rounds remain over-subscribed. We were able to fund 4 Transformational Impact Awards (TIAs), which we hope will lead to a real world impact for men in the medium term at a cost of £7.2m (FY24: 4 awards at a cost of £7.2m). We also continue to develop the sector as an attractive field by funding Research Innovation Awards and Early Career Fellows. We funded the UK’s involvement in international programs by providing £2 million to fund initiatives led by Movember.

2. Health Services, Equity and Improvement

Demand for the services we provide to men and their families living with prostate cancer has increased. We continued our specialist nurses helpline, our information services and peer support work; all funded through the donations we receive from the public. We spent £7.0m (2024: £5.3m) due to our expanded efforts.

3. Awareness

It is critical to our mission to raise awareness of prostate cancer across the UK. We spent £9.8m (2024: £9.6m) in this area through targeted campaigns. Our increasing prominence is increasing the effectiveness of our reach and spend.

4. Raising Funds

Our fundraising expenditure increased from £10.3m to £11.0m as we aimed to grow the number of new donors that support our cause. We continue to strategically invest in partnerships and philanthropy to drive the growth we have seen. We have ambitions to raise further funds in order that we can meet the needs of men and their families in the research we fund and support services we offer in the future.

5. Support costs

Our support costs have increased from £5.3m to £5.9m, primarily as a result of additional investment

11

made to upgrading our technology. During the year, we upgraded our CRM system to time and budget, in order that we can better support and engage with our supporters.

Balance sheet

Our balance sheet remains strong. Over the course of the year, we have increased our cash and short term deposits from £41.7m to £57.5m as a result of our strong in-year fundraising performance. The charity remains in a good position to meet our £45.3m commitment to long-term research projects (Note 7).The value of our investments remained consistent with last year during an unpredictable economic period at the reporting date.

Our treasury policy on page 13 provides information on how the charity invests balances held. We will reduce our cash balances as we pay research grants in line with contractually committed multiyear terms.

Our restricted reserves decreased from £4.3m to £2.1m at 31 March 2025 with unrestricted reserves increasing from £24.9m to £30.9m. Note 19 to the accounts provide further detail in respect of movements in funds.

Reserves policy

The charity operates within a reserves policy which is reviewed at least annually and as part of the charity’s budget and planning processes.

The Trustees review reserves levels to ensure there are adequate funds available to support the work of the charity. The charities’ Statement of Recommended Practice (SORP) categorises reserves as follows:

Our reserves policy and calculation methodology is based on Charity Commission best practice as outlined in CC19. This policy is designed to ensure the charity can continue its charitable work despite fluctuations in income and investment performance. This has become particularly relevant given the economic volatility of recent years, which increases the risk to our ability to fundraise and the value of our investments. Our policy is also designed to ensure we can meet our commitments in relation to research grant funding and reduce the impact in the unlikely event that of the charity’s closure.

Free reserves are defined as unrestricted funds minus any designated funds. They are held for:

Trustees agreed this updated reserves policy in December 2025.

Total free reserves are £30.9m (2024: £24.9m). This is in line with our policy and the charity actively reviews its funds against this.

12

Risk-Based reserve

The risk-based reserve identifies the necessary costs or potential income reductions that can be absorbed to maintain current operational levels. Prostate Cancer UK's strategy relies on income growth to achieve the desired impact. With 95% of the charity's income being voluntary, there is a high degree of uncertainty regarding income growth. The risk-based approach considers the profile of each income type.

The reserve target holds funds in the event that the crystallisation of our costs involves significant cost shocks to the organisation’s operations or research activities. Given a moderate risk appetite, the risk-based reserve target is between £9.0 million and £12.0 million.

Major commitments reserve

A reserve held is held for major multi-year research commitments. Based on a moderate risk approach, means that £7.0m - £9.0m will be held in this reserve.

Strategic Investment Reserve

Prostate Cancer UK may identify an opportunity to accelerate progress towards our vision that falls outside of the business planning cycle, or is a material change in activity that will stretch beyond one year. The Strategic Investment Reserve allows Prostate Cancer UK to invest in Strategic Projects that will accelerate our strategic progress for men. Based on our 2025–26 budget and assessment of the risk factors above, our Trustees recommend a range of between £6m - £9m to be held in the Strategic investment reserve.

Designated funds solely relates to the value of fixed assets being £0.00m as at 31 March 2025.

The charity has restricted reserves of £2.1m at the year end (2024: £4.3m). Of this, £1.6m relates to funds from the Movember Foundation. We have agreed a series of projects within research and survivorship that will draw down the entirety of this restricted fund over the next few years.

Treasury Policy

The charity has an Investment Policy, which is reviewed annually by Trustees.

The charity has a low risk appetite with regard to deposits, with a primary objective of capital preservation and a secondary objective of generating income. Deposits are currently restricted to cash or near-cash products, held in:

It is our policy to spread funds to mitigate risk and to take into account institutions’ credit ratings.

Balances held are managed in order to meet working capital requirements, with accessibility maintained should phasing assumptions for income or expenditure be changed.

From April 2023 we placed funds into a long term Sustainable Multi-Asset Fund to generate a higher investment return but still within a lower risk tolerance.

13

During the year ended 31 March 2025, our fixed term deposits have helped to mitigate the risk of capital erosion in the short term. Our Sustainable Multi-Asset Fund is continuing to grow despite the unpredictable economic environment. Its performance is regularly reviewed by the charity.

Grants Policy

Prostate Cancer UK is a member of the Association of Medical Research Charities (AMRC), who are dedicated to helping medical and health charities deliver high quality research that improves people’s lives. Our research grant funding is delivered in accordance with the standards and guidelines set by the AMRC (as certified through their 2020 quinquennial peer review audit). Our research funding is awarded through four different strands: Research Innovation Awards, Fellowship Awards, Transformational Impact Awards and any additional ad-hoc Major Awards.

Research Innovation Awards

This scheme supports bold, innovative research projects that have the real potential to impact the way prostate cancer is diagnosed and treated. The assessment of the proposals we receive consists of a two-stage process, with applications first triaged by our Research Advisory Committee. All shortlisted applications submit a more detailed proposal which are further assessed by a minimum of three independent expert reviewers. The applicants are then permitted to submit a response to the anonymised expert reviewers’ comments. Final funding recommendations are made by our Research Advisory Committee.

Fellowship Awards

Our fellowship awards support the most promising early career researchers to pursue a career in prostate cancer research. Awards are predominantly made through our Career Acceleration Fellowships, where received proposals are subject to independent expert review before being considered by our Scientific Committee. Applicants are shortlisted for interview by the Committee, following which final funding recommendations are made.

We also partner with other organisations such as the Medical Research Council and Academy of Medical Sciences to support prostate cancer research fellows who are recommended for funding through their schemes.

Transformational Impact Awards

This scheme supports large-scale research investments (up to £2m) covering high quality proposals focused on tackling the biggest challenges in prostate cancer. For these awards we follow a single application process, with all proposals assessed by at least three independent reviewers. Applicants may then respond to the anonymised reviewers’ comments, and all proposals are subsequently considered by our Scientific Advisory Board who shortlist applicants who are then interviewed before the final funding recommendations are made.

Bespoke Funding Calls & Costed Extensions to Grants

In addition to the above, we may also run bespoke, ad-hoc funding calls to support research in specific, strategically important areas. The approach for such schemes may vary depending on the focus, however as with our other schemes we adhere to the industry standards as set by the

14

AMRC. We also have a process in place to assess exceptional cases where additional funding is required towards our existing research grants (costed extension), where there is a high risk of nondelivery of the grant objectives due to unforeseen and unavoidable delays or issues.

Remuneration Policy

The charity’s remuneration policy is designed to attract, retain and motivate a high performing team to deliver the charity’s aims as well as to demonstrate to our stakeholders an effective use of charitable funds. The objectives of our remuneration policy are to:

Remuneration for colleagues is proposed by the Leadership Team and approved by the People Nominations and Remuneration Committee on behalf of the Board of Trustees. When setting pay levels, the charity gives consideration to external benchmark comparators, changes in the national average earnings index, affordability and other internal and external pressures including recruitment and retention.

Remuneration for the Executive Leadership Team and the Chief Executive is overseen by the People Nominations and Remuneration Committee on behalf of the Board of Trustees

The above policy applies to all colleagues, including the charity’s key management personnel (as defined on pages 6-8).

The annual salary of the Chief Executive is overseen by the People, Nominations and Remuneration Committee.

Related parties

Each year the Trustees and key management personnel are asked to declare key relationships so that the charity can identify any related party transactions. This is also a routine part of any board or committee meeting. Any such transactions are undertaken at arms’ length and detailed more fully within Note 24 to the accounts.

Public benefit

We have considered the Charity Commission’s guidance on public benefit when reviewing our aims and objectives and in planning future activities.

The public benefit of the charity is in mitigating the effect of prostate cancer and prostate disease in the United Kingdom. Our strategic aims and the charity’s activities are designed to achieve this benefit through a range of direct service delivery and support, and also through an extensive programme of funded research to improve the diagnosis and treatment of prostate cancer.

The beneficiaries of our work are men and their families – reached either directly or through healthcare professionals. Some of those who have benefited from our services are detailed in this

15

report. Our service is open to all men in the United Kingdom and their families, without charge.

As a result of the above, the Trustees consider that Prostate Cancer UK satisfies the public benefit test.

Principal risks and uncertainties

The top 5 risks to which the charity is exposed, as identified by the Trustees, are regularly reviewed and systems have been established to mitigate them. A risk register summarises the principal risks facing the charity, graded according to their likelihood and impact, and identifies actions to manage them. It is reviewed and updated by the Leadership Team each quarter, and reviewed three times a year by the Finance, Risk and Audit Committee. The Board of Trustees reviews the register annually, but any ‘red light’ issues are brought to their attention as they arise.

Potential risk Mitigations
Economic downturn
That our income falls and we are
unable to afford our operations and
research funding. 95% of our income
comes from donations, which are
subject to wider macro-economic
forces. There is a risk that
investments fall.		 We have an ambitious 5 year fundraising strategy
that will focus on growth of donors and income
across both mass fundraising, corporate and
philanthropic donations.
We closely monitor performance to date and future
pipeline. We use data, analysis and insight to drive
our decision making, both in established channels
and in new products.
We regularly review investment performance and
actively use of money markets to deliver best
available return on cash
Research: high expenditure but no
impact
That our research does not allow us
to achieve our strategic vision of
improving the health outcomes of
men in the future; either because the
outcome of the funding is negative or
because the areas funded will not
progress towards our goal.		 We maintain rigorous governance and review
mechanisms, including independent review of new
applications. We issue clear guidance around the
funding process to ensure applications are of high
quality and ready to fund. We will only fund where
it is of high scientific quality and the commitment
is affordable.
Large research projects are specifically reviewed by
the Board Research Council and may have
independent steering groups to assess the progress
against agreed milestones.
We track post funding progress, in order that we
can develop compelling case studies of the impact
of research.

16

Technology disruption
That we are subjected to cyber attack
or other technology failing that puts
business continuity or data at risk.		 IT infrastructure and services are subject to
regular external scrutiny, including Cyber
Essentials Plus certification, vulnerability
scanning, penetration testing and anti-virus
software
We work with external experts to that conduct
constantly monitor external threats to our
environment.
All staff complete mandatory compliance training
annually, to ensure they are aware of how to spot
and report suspicious activity.
Public perception and Brand
That Trust in our Brand comes into
disrepute. We are trusted to provide
health services and information on
risk areas, and also by the public for
funds to be used appropriately.		 Trust in our brand remains high and is closely
monitored.
Key stakeholder relationships will be fully vetted to
ensure they align with our values, including
adherence to our Code of Conduct and Ethical
Policy
Our fundraisers are inducted into the Institute of
Fundingcode ofpractice
Unable to attract and retain staff
That we fail to recruit and retain a
strong and robust workforce to meet
our strategic commitments, including
employees, could impact our ability to
deliver our ambitions for our
beneficiaries. This
may include a failure to embed an
inclusive workplace culture.		 We have strong mitigation plans in place to
manage adverse risks across retention,
recruitment, inclusion, health and safety and
safeguarding. Staff turnover is currently lower than
sector benchmarks.
We have developed an EDI plan and set up People
Networks to engage with staff and promote
diversity and inclusion across our organisation
We have introduced a new pay framework and
hybrid working policy to attract candidates and to
ensure staff are remunerated in line with the
market average.
We run and act on staff engagement surveys

Fundraising standards information

We take our responsibilities to our supporters very seriously and continue to ensure supporters have control over how we contact them, complying with UK Data Protection Legislation. We contact people by telephone, email and SMS only if they specifically agree to it and we are encouraged that a vast number of people are still responding warmly to our communications.

We are committed to giving everyone who comes into contact with us a positive experience that meets their needs, on their terms. As such, each time we communicate with our supporters, they can change their communication preferences.

17

We are a member of the Fundraising Regulator and adhere to its Code of Fundraising Practice. The Code of Fundraising Practice supports all our fundraising activities. For example, it is used within the training and monitoring of our professional fundraisers.

Our Board of Trustees continue to take a close interest in the programme of work, and we work hard to ensure our fundraising activities are compliant with all relevant rules and regulations, remain ethical and deliver to high standards.

We have a complaint handling process for members of the public that deals with complaints in an open and honest manner without prejudice. In 2024/25, we received 310 complaints relating to fundraising. This represents 0.001 % of all outbound communications and is at a similar level to the previous year. We regularly track and review all complaints so we can learn from them and update our processes and procedures in real time. Complaints are reported to the Fundraising Regulator where required.

The dedication and commitment of our supporters has shone through this year more than ever and we are hugely grateful to them for finding new ways to support us.

Third-party monitoring and protecting vulnerable people

This year we used third parties for telephone and private site fundraising activities.

All fundraising suppliers contractually agree to our own robust terms of engaging with our supporters which includes meeting the Fundraising Regulators’ Code of Fundraising Practice. Our agencies also supply a ‘People in vulnerable circumstances policy’ as part of those contracts which address how to recognise and protect people in these circumstances. We provide charity specific training to agency fundraisers before each campaign and undertake in-house and external mystery shopping. We are also signed up to the Chartered Institute of Fundraising mystery shopping programme. For our telephone agency and private sites (welcome calls) we undertake regular random call listening so they meet our expected standards and those of the Fundraising Code of Practice. They also provide details of any calls they believe to be a cause for concern, in line with their people in vulnerable circumstances policy. We listen to the call and decide what action should be taken. Any complaints are also given to us, with the call recording. We meet regularly with our third-party fundraisers to ensure contractual obligations are being met and to lead refresher training sessions.

We will never pressure anyone into giving a gift and will be respectful of the needs of any possible donor who may be in vulnerable circumstances or need extra care and support to make an informed decision. We do not take a donation if we know, or have good reason to believe, that a person lacks capacity to make a decision to donate, or is in vulnerable circumstances which mean they may not be able to make an informed decision. We ensure our fundraisers treat people fairly and with respect and explain the cause in a way which does not mislead people. We always respect a donor’s decision if they decide to stop giving.

All work carried out with third-party fundraising organisations adheres to legal requirements and best practice guidelines. There were no reportable compliance issues with fundraising standards, and we were the subject of no regulatory investigations by the Fundraising Regulator. Please contact data@prostatecanceruk.org if you would like a list of the third parties that we used.

18

Plans for the future

Prostate Cancer UK is committed to a future where no man dies of prostate cancer. We will continue our current strategy by raising awareness, funding high quality research and supporting men and the families living with the disease. We will continue our drive Black Health Equity as a priority across each area of our work.

1. Funding high quality research

As the largest funder of prostate cancer research in the UK, we are dedicated to supporting the brightest minds and the most innovative projects. For every £1 donated, our researchers attract an additional £3 in funding. Our Transformation Impact Awards (TIAs) provide significant grants to advance promising discoveries. We will continue to connect our prostate cancer research and healthcare professional community locally, nationally and globally, through our impactful programmes which motivate the best minds to work together and share knowledge.

We are focused on early diagnosis and better treatment options. Our groundbreaking TRANSFORM screening trial is ongoing and will provide the evidence needed for a safe and effective screening programme.

2. Advancing Black Health Equity

Black Health Equity is a strategic priority for the year ahead. We will invest resources into answering the questions that demonstrate what the key barriers Black men face with Real World Evidence. Through this, we expect to have the foundations to drive improvements in outcomes for this high risk group.

3. Raising Awareness

Our 30-second online risk checker tool has empowered 1.1 million men to understand their risk of prostate cancer this year so no man dies of prostate cancer because he did not know his risk factors or that he’s entitled to a PSA blood test from his GP if he chooses. Through targeted advertising campaigns and partnerships, we are spreading lifesaving messages to reach more men.

4. Supporting Men to navigate prostate cancer through our services

Our Specialist Nurses offer expert advice and support through various channels, including phone, live chat, email, and WhatsApp. We will continue to provide high quality, trusted, health information. We are also influencing to ensure that men have access to the best possible care and support.

5. Growing our income

We need to grow our income sustainably, in order that we can serve the growing number of men and their families at risk of, or living with the disease. We are reliant on donations to fund leading research, provide support services and continue to raise awareness of the risk factors in to England’s most common cancer.

Streamlined Energy and Carbon Reporting for the year to 31 March 2025

This report summarises the energy usage, emissions, efficiency actions and performance for Prostate Cancer UK under the Streamlined Energy and Carbon Reporting regulations. In preparing this report, we have complied with The Companies (Directors’ Report) and Limited Liability Partnerships (Energy

19

and carbon) Regulations 2018, incorporating the UK Government’s policy on Streamlined Energy and Carbon Reporting (‘SECR’), which came into force on 1 April 2019.

The charity operates from one office and our energy use is related to:

For the year to 31 March 2025, the charity’s UK energy use was 214,490kWh.

Our CO2e emissions were as follows:

Our CO2e emissions were as follows:
Tonne C02e 2025
Scope 1: direct emissions 16.9
Scope 2: indirect emissions office space
emissions		 21.6
Scope 3: indirect transportation emissions
due to staff travel		 5.0
Total 43.5

In line with the sector, the charity has chosen an intensity ratio based on Full-Time Equivalent (FTE) staff members as reported within the notes to the financial statements. For the reporting period, our ratio was as follows:


ratio was as follows:
Intensity metric 2025
tCO2e/FTE 0.20

Energy efficiency improvements

Prostate Cancer UK has limited control over energy consumption and greenhouse gas emissions, as we do not own our office spaces, and the vehicles used for business travel are owned by staff. However, we remain committed in our endeavour for energy efficiency and this year implemented the following actions:

Section 172(1) statement

Section 172 of the Companies Act 2006 requires the Directors to act in the way they consider, in good faith, would be most likely to promote the success of the Charity to achieve its charitable purposes. The Act states that in doing so, the Directors should have regards, amongst other matters, to:

20

a) The likely consequence of any decision in the long term

As the charity comes to the end of a three year strategy which saw us increase our charitable activity, we will review how we performed and take learnings from this to establish a new 10 year strategy which will push our organisation forward and ensure it is sustainable for the long term. As we develop this strategy, we will continue to budget in a way which is sustainable and delivers the greatest impact for men affected by prostate cancer.

b) The interests of the company’s employees

Our colleagues play a pivotal role in driving the charity forward therefore we value their input and engagement in to how we work. We have regular staff surveys and address issues raised through this as soon as possible. Our people networks play a key role in our journey to become an equitable, diverse and inclusive workplace. We have signed up to the Race at Work Charter to help tackle the barriers that ethnic minority people face in the workplace. We have weekly allstaff meetings and monthly townhalls where colleagues can keep up to date with what’s happening across the charity and ask questions of the leadership team. All colleagues have access to wellbeing support and we have mental health first aiders who can support colleagues on a 1:1 basis.

c) The need to foster the company’s business relationships with suppliers, customers and others

Everyone that we interact with has an important role to play in helping us achieve our goals from researchers and those affected by prostate cancer to suppliers, volunteers and supporters. We seek to obtain regular feedback from everyone involved to ensure that we’re doing the best we can to help deliver the biggest impact to men. In respect of our suppliers, we pay them promptly with over 95% of suppliers being paid within 60 days.

d) The impact of the company’s operations on the community and the environment

At our offices, we undertake a number of activities which reduce our waste and energy usage such as recycling, energy efficient light bulbs, light timers and so forth while we take measures to reduce our energy usage as set out in our Streamlined Energy and Carbon Reporting statement above. Outside of the office, we encourage staff to use public transport where practical.

e) The desirability of the company maintaining a reputation for high standards of business conduct

We have a range of internal and external policies which govern how we act and promote the organisation’s values. These include policies on whistleblowing, code of conduct and ethics internally, while our external policies cover fundraising, research and our organisational values. Having a high standard of business conduct ensures that not only are we are a good place to work, we are an organisation that stakeholders want to work and be associated with.

f) The need to act fairly as between members of the company

Our members are our Board of Trustees who have equal rights to ensure we act fairly.

21

Trustees’ responsibilities statement

The Trustees (who are also Directors of Prostate Cancer UK for the purposes of company law) are responsible for preparing this Annual Report (including the Strategic Report) and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and the group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity’s constitution.

They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditor

On 18 November 2024, the Company's auditors changed their name from Haysmacintyre LLP to HaysMac LLP.

HaysMac LLP has been appointed as the charity’s auditor. The Trustees review the appointment of the auditor annually and have delegated power to set the auditor’s remuneration to the Finance, Risk and Audit Committee. The Trustees’ Annual Report and Strategic Report were approved by the Board of Trustees on 3 December 2025 and authorised to be signed on its behalf by:

Doris Olulode | Chair

22

Independent Auditor’s Report to the members and Trustees of Prostate Cancer UK

Opinion

We have audited the financial statements of Prostate Cancer UK for the year ended 31 March 2025 which comprise the Group and Charity Statement of Financial Activities Including Summary Income and Expenditure Accounts, the Group and Charity Balance Sheets, the Group Statement of Cash Flows, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

23

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Report (which incorporates the strategic report and the directors’ report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charity Accounts (Scotland) Regulations (as amended) requires us to report to you if, in our opinion:

Responsibilities of trustees for the financial statements

As explained more fully in the trustees’ responsibilities statement set out on page 22, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

24

In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the group and the environment in which it operates, we identified that the principal risks of non-compliance with laws and regulations related to the Companies Act 2006 and the Charities Act 2011 and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered other factors such as compliance with the fundraising regulations, income tax, payroll tax and sales tax.

We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and concluded that the risk was low. Audit procedures performed by the engagement team included:

Discussions with management including consideration of known or suspected instances of noncompliance with laws and regulation and fraud, and in particular with instances of non-compliance with the fundraising regulations;

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities

25

occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Richard Weaver (Senior Statutory Auditor) For and on behalf of HaysMac LLP, Statutory Auditors 10 Queen Street Place, London, EC4R 1AG

Date: 5 December 2025

26

Group statement of financial activities including summary income and expenditure account for the year ended 31 March 2025

INCOME FROM
Notes
Donations and legacies
2
Other trading activities
3
Investments
4
Total
EXPENDITURE ON
Raising funds
2
Charitable activities
6
Total
Net income / (expenditure)
5
Unrealised gain on investments
13
Transfers between funds
19
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward
19		 Unrestricted
Restricted
Total
Total
Funds
Funds
2025
2024
£’000
£’000
£’000 £’000
36,186
6,356
42,542 40,962
613
-
613
683
2,363
-
2,363
2,176
39,162
6,356
45,51843,821
10,978
-
10,97810,337
26,843
4,207
31,05041,149
37,821
4,207
42,02851,486
1,341
2,149
3,490(7,665)
310
-
310
995
4,353
(4,353)
-
-
6,004
(2,204)
3,800(6,670)
24,939
4,337
29,27635,946
30,943
2,133
33,07629,276

The comparative figures for each fund are shown in the notes to the accounts.

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above.

The notes on pages 31-53 form part of these financial statements.

27

Charity statement of financial activities including summary income and expenditure account for the year ended 31 March 2025

INCOME FROM
Donations and legacies
Investments
Total
EXPENDITURE ON
Raising funds
Charitable activities
Total
Net (expenditure)
Unrealised gain on investments
Transfers between funds
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 Unrestricted
Restricted
Total
Total
Funds
Funds
2025
2024
£’000
£’000
£’000
£’000
36,573
6,356
42,929
41,359
2,363
-
2,363
2,176
38,936
6,356
45,292
43,535
10,669
-
10,669
10,051
26,926
4,207
31,133
41,149
37,595
4,207
41,802
51,200
1,341
2,149
3,490(7,665)
310
-
310
995
4,353
(4,353)
-
-
6,004
(2,204)
3,800(6,670)
24,939
4,337
29,276
35,946
30,943
2,133
33,076
29,276

The comparative figures for each fund are shown in the notes to the accounts.

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above.

The notes on pages 31-53 form part of these financial statements.

28

Balance sheets as at 31 March 2025

GROUP GROUP CHARITY CHARITY
Notes 2025 2024 2025 2024
£’000 £’000 £’000 £’000
Fixed assets
Intangible assets 11 - - - -
Tangible assets 12 - 15 - 15
Investments 13 16,110 15,928 16,110 15,928
Total fixed assets 16,110 15,943 16,110 15,943
Current assets
Stocks 14 108 126 - -
Debtors 15 9,392 14,153 9,735 14,338
Short-term deposits 27,000 17,733 27,000 17,733
Cash at bank and in hand 30,526 23,928 30,180 23,776
Total current assets 67,026 55,940 66,915 55,847
Liabilities:
Creditors: Amounts falling due within one 16 20,692 13,116 20,581 13,023
year
Net current assets 46,334 42,824 46,334 42,824
Total assets less current liabilities 62,444 58,767 62,444 58,767
Creditors: Amounts falling due after more
than one year 17 29,368 29,491 29,368 29,491
Net assets 33,076 29,276 33,076 29,276
Funds:
Restricted income funds 19 2,133 4,337 2,133 4,337
Unrestricted funds
General 19 30,943 24,924 30,943 24,924
Designated 19 - 15 - 15
30,943 24,939 30,943 24,939
Total funds 33,076 29,276 33,076 29,276

Approved and authorised for issue by the Board of Trustees on 3 December 2025 and signed on its behalf by:

Doris Olulode, Chair

Company registration number 02653887

The notes on pages 31-53 form part of these financial statements.

29

Group statement of cash flows for the year ended 31 March 2025

Notes
Cash flows from operating activities:
Net cash provided by/(used in)
operating activities
23
Cash flows from investing activities:
Dividends and interest from investments
4
Purchase of investments
13
Net cash provided by/(used in)
investing activities
Change in cash and cash equivalents
in the reporting period
Cash and cash equivalents at
the beginning of the
reporting period
Cash and cash equivalents at the end
of the reporting period
Changes in net debt:
Cash and cash equivalents at start of year
Cash flows
Cash and cash equivalents at end of year		 2025
2024
£’000
£’000
£’000
£’000
13,502
9,069
2,363
2,176
-
(15,012)
57,526
41,661
41,661
15,865
57,526
2,363
(12,636)
15,865
(3,767)
41,661
45,428		 2025
2024
£’000
£’000
£’000
£’000
13,502
9,069
2,363
2,176
-
(15,012)
57,526
41,661
41,661
15,865
57,526
2,363
(12,636)
15,865
(3,767)
41,661
45,428
57,526

The notes on pages 31-53 form part of these financial statements.

30

Notes forming part of the financial statements for the year ended 31 March 2025

1 General information and basis of preparation

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared under the historical cost convention in accordance with the Financial Reporting Standard Applicable in the UK and Republic of Ireland (FRS102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS102)) and the Charities Act 2011 and the Companies Act 2006.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Going concern

Accounting policies

Income

31

approved estate accounts. Income from reversionary interest in legacies is recognised once legal title has passed to the charity. Amounts for pecuniary and residuary cases not included in legacy income (such as those with corrupt title and contentious case) are disclosed as a contingent asset in Note 15.

Expenditure

32

are members. The assets of the scheme are held separately from those of the charity in independently administered funds. Contributions in respect of the scheme are charged against net incoming resources in the year in which they are due.

Intangible fixed assets and amortisation

Software 33%

Tangible fixed assets and depreciation:

Lease improvements over period of Lease Computer equipment and 33% website developments Fixtures and fittings 33%

Investments

Stock

Short term deposits

33

Financial assets and liabilities

Fund accounting

Restricted:

These are funds that can only be used for particular restricted purposes. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Unrestricted:

These are funds which can be used in accordance with the charitable objects at the discretion of the Board of Trustees.

Designated:

These are funds set aside by the Board of Trustees out of unrestricted funds for specific purposes.

Grant commitments and long term liabilities

Financial Instruments

34

Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

35

2 Income from donations and legacies and expenditure on raising funds

Income
2025		 2024
Individual donors and legacies
Community and events
Corporate donors
Major donors and charitable trusts
Donated goods and services
Government grants
Of which in 2024:
Restricted
Unrestricted		 Unrestricted
Restricted Total income
£’000
£’000
£’000
18,268
417
18,685
12,776
-
12,776
2,503
3,600
6,103
2,616
2,339
4,955
23
-
23
-
-
-		 Total
£’000
16,793
12,939
2,806
2,450
29
5,945
36,186
6,356
42,542		 40,962
7,969
32,993
40,962

The income from government grants consists of £NIL from the National Institute of Health and Care Research (2024: £4,000k) and £NIL from the Medical Research Council for research (2024: £1,945k).

Individual donors and legacies
Community and events
Corporate donors
Major donors and charitable trusts
Appeal
Trading
Investment management fees		 Expenditure on
raising funds
2025
2024
Direct
costs
Support
costs
Total
costs
Total
costs
£’000
£’000
£’000
£’000
4,788
871
5,659
4,889
3,012
548
3,560
3,696
509
93
602
732
239
43
282
597
343
63
406
-
220
-
220
280
211
38
249
143
9,322
1,656
10,978
10,337

All expenditure on raising funds was unrestricted in both years.

For a breakdown of prior year comparatives see Note 25.

36

3 Trading subsidiary

The results of the Charity’s wholly-owned trading subsidiary, Prostate Cancer Trading Limited (06157784), which are incorporated in these consolidated accounts, are as follows:

Turnover
Cost of goods sold
Gross profit
Administrative expenses
Net profit
Income transferred by Gift Aid
Retained in subsidiary
Total current assets as at 31 March
Total current liabilities as at 31 March
Net assets held as at 31 March		 2025
2024
Total
Total
£'000
£'000
613
683
(220)
(280)
393
403
(159)
(221)
234
182
(234)
(182)
-
-
2025
2024
Total
Total
£'000
£'000
617
430
(617)
(430)
-
-

4 Investment income

4Investment income
Interest income
Distributions from fund		 2025
2024
£'000
£'000
2,363
1,823
-
353
2,363
2,176

5 Net income for the year

This is stated after charging:

Depreciation and amortisation
Auditor’s remuneration – audit services
Auditor’s remuneration – other services
Operating lease rentals – property		 2025
2024
£'000
£'000
15
105
42
40
5
5
645
610

37

6 Charitable activities

6Charitable activities
Research
Health Services, Equity and
Improvement
Awareness
Of which in 2024:
Restricted
Unrestricted		 Direct
Support
costs
costs
£’000
£’000
13,879
311
5,321
1,656
7,560
2,323		 2025 2024
Total costs


£’000

14,190

6,977

9,883		 Total
£’000
26,227
5,300
9,622
26,760
4,290
31,050		 41,149
3,913
37,236
41,149

For a breakdown of prior year comparatives see Note 25.

38

7 Grants awarded

Grant commitments comprise research commitments. Research grants are awarded to fund researchers in the key areas of better treatment, better diagnosis and smarter data in line with our Research strategy.

2025 2024
Total Total Better Better Smarter
Treatment
Diagnosis
Data
Research grants were awarded
to the following institutions:		 £’000 £’000
UniversityCollege London 3,478 3,707
University of Oxford 2,662 430
University of Southampton 1,877
Newcastle University 1,133 635
Imperial College London 819 12,547
University of Aberdeen 661
Queen ‘s UniversityBelfast 326
Keele University 324
Institute of Cancer Research 236 3,478
Medical Research Council 129
Queen MaryUniversityof London 1,359
Open University 640
The Universityof Manchester 594
King's College London 581
Cardiff University 518
London School of Hygiene &
Tropical Medicine		 345
University of Nottingham 272
University of Central Lancashire 80
11,645 25,186

Research grants awarded in the year were for the following projects:

39

Reconciliation of research grants payable:
Commitments at 1 April
Commitments made in the year
Grant adjustments and cancellations
Grants paid during the year
Commitments at 31 March
Outstanding research commitments at 31 March are payable
as follows:
Within one year (Note 16)
After more than one year (Note 17)		 2025
2024
£'000
£'000
40,500
20,386
11,645
25,186
(69)
(22)
(6,821)
(5,050)
45,255
40,500
2025
2024
£'000
£'000
16,230
11,203
29,025
29,297
45,255
40,500

The split of future payment dates is based upon contractual terms.

40

8 Board of Trustees and employee information

No member of the Board of Trustees received any remuneration from the charity in either year. Directly incurred expenses are reimbursed, if claimed.

Trustees' expenses represents the payment or reimbursement of travel and subsistence costs or other out of pocket expenses which for the year were £8,616 in total to ten trustees (2024: £1,604 to four trustees).

The key management personnel of the charity comprises the members of the Board of Trustees, the Chief Executive and the Leadership Team, as stated on pages 6-8 of the Annual Report. The total employee benefits of the key management personnel of the charity were £975,085 paid to eight posts (2024: £827,987 paid to seven posts). Interest free travel loans of £NIL were provided to key management personnel (2024: £NIL). The amount outstanding at the year end was £NIL (2024: £NIL).

The above benefits relate to the Chief Executive and Leadership Team only.

The average full-time equivalent number of persons employed by the group during the year was:

Fundraising
Research
Health Services, Equity and Improvement
Communications
Finance, Governance and Technology and People & Culture		 2025
2024
49
49
11
10
46
45
71
68
41
41
218
213

The average number of employees (head count based on number of staff employed) during the year was as follows:

the year was as follows:
Fundraising
Research
Health Services, Equity and Improvement
Communications
Finance, Governance and Technology and People & Culture		 2025
2024
53
52
11
10
51
48
75
70
43
41
233
221

41

8 Board of Trustees and employee information (continued)

Amounts paid in respect of employees were:

Salaries and wages
Social security costs
Pension costs
Termination payments
Total emoluments of employees
Agency staff		 2025
2024
£'000
£'000
9,941
9,050
1,107
966
1,077
975
126
36
12,251
11,027
46
112
12,297
11,139

The number of employees whose emoluments for the year were over £60,000 after salary sacrifice was:

£60,001 to £70,000
£70,001 to £80,000
£80,001 to £90,000
£90,001 to £100,000
£100,001 to £110,000
£120,001 to £130,000
£130,001 to £140,000		 2025
2024
11
13
6
2
1
1
2
3
4
-
-
1
1
-

The charity made pension contributions under a defined contribution scheme amounting to £224 (2024: £151k), in respect of the 25 employees in the table above (2024: 20).

Trustee indemnity insurance for the year was set at £5 million cover collectively at a cost of £5k (2024: £6k).

Termination payments totalled £126k for the year (2024: £36k) paid as compensation for loss of employment.

9 Pension costs

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension cost, which represents contributions paid by the charity to these funds, amounted to £1,077k (2024: £975k). The amount payable at the year end was £87k (2024: £84k).

42

10 Analysis of support costs

The breakdown of support costs and how these are allocated is shown below.

2025
Raising
Charitable
Total costs
funds
activities
£'000
£'000
£'000
Staff and similar
925
2,398
3,323
Supplies and services
314
815
1,129
Premises costs
403
1,041
1,444
Depreciation
1
2
3
Governance costs
13
34
47
1,656
4,290
5,946
Governance costs comprise:
2025
Total costs
£'000
Audit fees
42
Trustee indemnity insurance
5
47
For a breakdown of prior year comparatives see Note 25.
11Intangible fixed assets – Group and Charity
Cost
At 1 April 2024
Disposal
Additions
At 31 March 2025
Amortisation
At 1 April 2024
Disposal
Charge for the year
At 31 March 2025
Net book value
Net book value at 31 March 2024
Net book value at 31 March 2025		 Raising
Charitable
funds
activities
£'000
£'000
925
2,398
314
815
403
1,041
1
2
13
34		 2025 2024

Total costs


£'000

3,323

1,129

1,444

3

47		 Total costs
£'000
3,141
778
1,289
23
46
1,656
4,290
5,946		 5,277
2025 2024
Total costs
£'000
42
5		 Total costs
£'000
40
6
47 46
Software
£’000
28
-
-
28
28
-
-
28
-
-

43

12 Tangible fixed assets – Group and Charity

Cost
At 1 April 2024
Additions
Disposals
Transfers
At 31 March 2025
Depreciation
At 1 April 2024
Charge
Disposals
Transfers
At 31 March 2025
Net book value
Net book value at 31 March
2024
Net book value at 31 March
2025		 Lease
Improvements
Fixtures
and
fittings
Computer
equipment and
website
development
Total
£'000
£'000
£'000
£'000
906
219
691
1,816
-
-
-
-
-
-
(225)
(225)
-
-
-
-
906
219
466
1,591
906
219
676
1,801
-
-
15
15
-
-
(225)
(225)
-
-
-
-
906
219
466
1,591
0
0
15
15
0
0
0
0

44

13 Investments – Charity

2025 2024
£’000 £’000
At Market Value
UK listed investments – Sustainable Multi-Asset Fund (SMAF) 16,098 15,916
Investments in UK unlisted companies (see below) 12 12
Investment in subsidiaries (see below) - -
Total investments 16,110 15,928
SMAF Investments Investment in Total
in UK unlisted Subsidiaries
companies
£’000 £’000 £’000 £’000
Movements
At 1 April 15,916 12 - 15,928
Additions - - - -
Disposals - - - -
Unrealised gains 310 - - 310
Investment management (128) - - (128)
fees
At 31 March 16,098 12 - 16,110

The historical cost of the Charity’s investments at 31 March 2025 was £15,640k (2024: £15,012k).

The Charity’s listed investments are managed on its behalf by Cazenove & Co.

The Charity’s investment in its active subsidiary undertaking Prostate Cancer Trading Limited (06157784) amounted to £100, being 100 ordinary shares, representing the entire share capital. The Charity also wholly owns the following dormant companies: The Prostate Cancer Charity Limited (08183613), Prostate Cancer Research Foundation (05926197) and Prostate Action (07149009), which are not consolidated in these financial statements.

The Charity has a 9% holding in GlycoScoreDx Limited (12766216) to develop opportunities for intellectual property income. This was acquired at nil cost but, during 2024, the Charity paid £12k to maintain its shareholding at 9%.

45

14 Stock

14 Stock
Stock for resale
15 Debtors		 Group
Charity
2025
2024
2025
2024
£'000
£'000
£'000
£'000
108
126
-
-
15 Debtors
Trade debtors
Amounts due from subsidiary undertaking
Prepayments
Accrued income
Other debtors
Sub-total
Movember Foundation accrued income <1yr
Movember Foundation accrued income >1yr
Total debtors		 Group
Charity
2025
2024
2025
2024
£'000
£'000
£'000
£'000
214
3,024
209
2,890
-
-
507
337
1,239
854
1,235
849
5,035
6,373
4,880
6,360
34
69
34
69
6,522
10,320
6,865
10,505
2,438
1,665
2,438
1,665
432
2,168
432
2,168
9,392
14,153
9,735
14,338

The group has been notified of legacies amounting to approximately £6.3m (2024: £7.0m) which have not been included in the financial statements as the recognition criteria in line with the Charities SORP had not been met at the year end.

There are no specific security or repayment terms in respect of the working capital agreement with the subsidiary company.

The Movember Foundation confirms the total balance due to Prostate Cancer UK each year. Cash is received in line with agreed programme committed expenditure.

46

16 Creditors – falling due within one year

16 Creditors – falling due within one year
Trade creditors
Research commitments
Other taxes and social security
Accruals and deferred income
Other creditors		 Group
Charity
2025
2024
2025
2024
£'000
£'000
£'000
£'000
861
601
835
597
16,230
11,203
16,230
11,203
388
306
355
277
895
882
879
854
2,318
124
2,282
92
20,692
13,116
20,58113,023

Included in the above is deferred income relating to fundraising activities taking place after the year end as follows:

Balance at 1 April
Amounts released to incoming resources
Amount deferred in the year
Balance at 31 March		 Group
2025
2024
Charity
2025
2024
£'000
-
£'000
-
£'000
-
£'000
-
-
-
-
-
57
-
57
-
57
-
57
-

17 Creditors – falling due after more than one year

Research commitments
Other creditors		 Group
Charity
2025
2024
2025
2024
£'000
£'000
£'000
£'000
29,025
29,297
29,025
29,297
343
194343
194
29,368
29,491
29,368
29,491

47

18 Analysis of group net assets between funds

Fixed assets (Note 11, 12 and 13)
Current assets
Liabilities due within one year
Liabilities due after more than one year
Net assets at 31 March		 General
funds
Designated
funds
Restricted
funds
Total funds
£'000
£'000
£'000
£'000
16,110
-
-
16,110
61,824
-
5,201
67,025
(17,976)
-
(2,715)
(20,691)
(29,015)
-
(353)
(29,368)
30,943
-
2,133
33,076

For a breakdown of prior year comparatives see Note 25.

19 Movement in funds – Group

Restricted funds:
Movember Foundation
Other restricted funds:
Research
Specialist Nurses Service
Other restricted funds
Total other restricted funds
Total restricted funds
Unrestricted funds
Designated funds:
Fixed asset reserves
Total designated funds
Total unrestricted funds
Total funds		 As at
1 April
Incoming
Outgoing
Transfers
As at 31
March
£'000
£'000
£'000
£'000
£'000
3,824
0
(2,180)
-
1,644
359
5,476
(1,073)
(4,353)
409
-
-
-
-
-
154
880
(954)
-
80
513
6,356
(2,027)
(4,353)
489
4,337
6,356
(4,207)
(4,353)
2,133
24,924
39,472
(37,806)
4,353
30,943
15
-
(15)
-
-
15
-
(15)
-
-
24,939
39,472
(37,821)
4,353
30,943
29,276
45,828
(42,028)
-
33,076

The transfers between funds reflect adjustments made as a result of reconciliations during the year. For a breakdown of prior year comparatives see Note 25.

48

20 Purposes of restricted funds

Movember Movember Foundation income from its campaigns is
Foundation restricted to spend on research, health equity and
survivorship services for men with prostate cancer.
Research Funding received to support either specific
research awards or to be put towards other
unfunded research activity.
Other restricted Funding for projects other than research
funds activity

21 Purpose of designated funds

Fixed asset reserves - Amount representing the net investment in intangible and tangible fixed assets.

49

22 Commitments under operating leases

The group has commitments under operating leases due within the periods stated below:

:
Less than one year
Two - five years
Greater than five years		 Property
2025
2024
£'000
£'000
749
415
2,672
2,998
-
398
3,421
3,811

23 Note to group statement of cash flows

Reconciliation of net income/(expenditure) to net cash inflow from operating activities.

Net (expenditure) for the reporting period (as per the
statement of financial activities)
Adjustments for:
Investment income
Unrealised investment gain
Investment fees deducted from portfolio
Depreciation charges
Decrease/(increase) in stocks
Decrease/(Increase) in debtors
Increase in creditors
Net cash provided by operating activities		 2025
2024
£'000
£'000
3,800
(2,363)
(6,670)
(2,176)
(310)
(995)
128
79
15
105
18
(23)
4,761
(2,054)
7,453
20,803
13,502
9,069

24 Related party transactions

Aggregate donations received from trustees, key management personnel and connected parties during the year amounted to £2,771 (2024: £4,166).

Event and merchandise purchases by trustees, key management personnel and connected parties amounted to £137 (2024: £166).

During the year, the Charity made a grant of £38,000 to the Academy of Medical Sciences (2024: £38,000) of which Paul Stewart, a Trustee, was Acting President.

During the year, the Charity paid subscription fees of £18,325 at the market rate to the Association of Medical Research Charities where the partner of a member of key management personnel became a Director during the year.

There were no other related party transactions in either year.

50

25 Comparative note only

Note 2 - Income from donations and legacies and expenditure on raising funds

Individual donors and legacies
Community and events
Corporate donors
Major donors and charitable trusts
Donated goods and services
Government grant
Individual donors and legacies
Community and events
Corporate donors
Major donors and charitable trusts
Trading
Investment management fees		 Income
2024
Unrestricted
Restricted
Total income
£’000
£’000
£’000
16,714
79
16,793
12,939
-
12,939
2,425
381
2,806
886
1,564
2,450
29
-
29
-
5,945
5,945
32,993
7,969
40,962
Expenditure on raising funds
2024
Direct costs
Support costs
Total costs
£’000
£’000
£’000
4,226
663
4,889
3,195
501
3,696
633
99
732
516
81
597
280
-
280
123
20
143
8,973
1,364
10,337

Note 6 - Charitable activities

Note 6 - Charitable activities
Research
Support and influencing
Awareness		 2024
Direct
Support
Total costs
costs
costs
£’000
25,949
£’000
278
£’000
26,227
4,048
1,252
5,300
7,239
2,383
9,622
37,236
3,913
41,149

51

25 Comparative note only (continued)

Note 10 - Analysis of support costs

2024
Raising funds Charitable Total costs
activities
£'000 £'000 £'000
Staff and similar costs 812 2,329 3,141
Supplies and services 201 577 778
Premisescosts 333 956 1,289
Depreciation 6 17 23
Governancecosts 12 34 46
1,364 3,913 5,277

Note 17 - Analysis of group net assets between funds

Fixed assets (Note 11, 12 and 13)
Current assets
Liabilities due within one year
Liabilities due after more than one year
Net assets at 31 March		 General funds
Designated Restricted Total funds
funds
funds
2024
£'000
£'000
£'000
£'000
15,928
15
-
15,943
45,147
-
10,793
55,940
(8,701)
-
(4,415)
(13,116)
(27,450)
-
(2,041)
(29,491)
24,924
15
4,337
29,276

52

25 Comparative note only (continued)

Note 18 Movement in funds-Group

Restricted funds: Movember
Foundation
Other restricted funds:
Research
Specialist Nurses Service
Other restricted funds
Total other restricted funds
Total restricted funds
Unrestricted funds
Designated funds:
Fixed asset reserves
Total designated funds
Total unrestricted funds
Total funds		 As at
Incoming
Outgoing
Transfers
As at
1 April
£'000
£'000
£'000
£'000
31 March
£'000
5,368
1
(1,545)
3,824
2,024
7,609
(6,832)
(2,442)
359
-
99
(99)
-
-
73
260
(179)
-
154
2,097
7,968
(7,110)
(2,442)
513
7,465
7,969
(8,655)
(2,442)
4,337
28,361
36,847
(42,726)
2,442
24,924
120
-
(105)
-
15
120
-
(105)
-
15
28,481
36,847
(42,831)
2,442
24,939
35,946
44,816
(51,486)
-
29,276

The transfers between funds reflect adjustments made as a result of reconciliations during the year.

53

VOU YOU THANK YOU YO vou THANK YOU YOU You Yo THANK YOU Y, We're so grateful to everyone who has supported us over the past year. In particular, we'd like to thank the following supporters: Our Patron HRH The Duchess of Gloucester, LG, GCVO, DStJ, CD Our volunteers and Hubs Our donors who wish to remain anonymous All those who honoured someone with an engraving on our Memorial Sculpture Andrew Pitt John Black Charitable Foundation John Bloor OBE John Warren Jones Joron Charitsble Trust Ladbrokes Coral Trust Lazard Asset Management League Managers Association Lochlands Trust Angela Milne Bob Willis Fund Bothwell Charitable Trust Lord Leverhulme's Charitable Trust Brew York Malcolm Strong Marks and Spencer Marston's PLC Cecil Pilkington Charitable Trust Charles Tyrwritt Constance Travis Charitable Trust Matchroom Sport Foundation Michael Metcalf David Sullivan Doncaster Rovers FC Mike Tye Miva Foundation Douglas Cooke Dudley and Geoffrey Cox Charitable Trust Essity UK Florian Charitable Trust MOBOAwards Moss Mrs J B Wood's Charitable Trust Garfield Weston Foundation Omaze UK The Gerald and Gail Ronson Family Foundation Orbital Fasteners Order of Friars Minor Provincial Curia Gerry Pack HowDidiDo Media Ltd Paddy Power Paul Thompson Peacock Charitable Trust Iceland Foods Charitable Foundation Infinis Energy

WOOD rNAfft]K YOU THANK You YO THANK You YollJ fNAN YOU YOU THANK YOU YNIINK Y, Pentel Stationery Peter Stormonth Darling Charitable Trust phs Group Professional Darts Corporation Professional Golfers Association Foundation The Louis and Valerie Freedman Charitable Settlement The Mike Gooley Trailfinders Charity The National League The Patrick & Helena Frost Foundation Prostate United Queens Park Rangers FC R J and A H Daniels Charitable Trust The Pickup Family The Rose Foundation Ralph and Elizabeth Aldwinckle Roger Wiltshire ShareGift The Simon Gibson Charitable Trust The Sunset Charitable Trust The W A Handley Charity Trust The Willie and Mabel Morris Charitable Trust Sheffield Wednesday FC Sky Sports talkSPORT The Wyfold Charitable Trust Thomas Allen The 3Ts Charitable Trust Tom and Sheila Springer Charity Tottenham Hotspur FC Tyre Pros Wolverhampton Wanderers FC The A and R Woolf Charitable Trust The Beare83 Foundation The Betting and Gaming Council The Cranbrook Foundation The Fieldrose Charitable Trust The Freddie Green And Family Charitable Foundation Youi The Grace Trust The Henry Lumley Charitable Trust The IMP Trust The Jane & James Kessler Family Charitable Trust The Joseph and Lilian Sully Foundation The Kenneth & Susan Green Charitable Foundation The Lord Leonard and Lady Estelle Wolfson

prostatecanceruk.org Prostate Cancer UK @ProstateUK prostatecanceruk in Prostate Cancer UK lil , PROSTATE CANCERUK Prostate Cancer UK is a registered charity in England and Wales110055411 and in Scotland ISC0393321. Registered company number 02663887.